The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID‐19: A meta‐analysis of randomized trials
Abstract Background Overactivation of the NLR family pyrin domain containing 3 (NLRP3) inflammasome can lead to severe illness in patients with coronavirus disease‐2019 (COVID‐19). The NLRP3 inhibitor, colchicine, therefore, appears to be promising for the treatment of COVID‐19. Aims We aimed to per...
Saved in:
| Main Authors: | Chia Siang Kow, Learn‐Han Lee, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan, Long Chiau Ming, Hui Poh Goh |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-02-01
|
| Series: | Immunity, Inflammation and Disease |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iid3.562 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Reevaluating thromboprophylaxis in COVID-19 outpatients: the case for a targeted, risk-based approach
by: Chia Siang Kow, et al.
Published: (2025-03-01) -
Colchicine in stroke prevention: potential benefits and limitations of an anti-inflammatory therapy
by: Osman Corbali, et al.
Published: (2025-02-01) -
The Emerging Role of Colchicine to Inhibit NOD-like Receptor Family, Pyrin Domain Containing 3 Inflammasome and Interleukin-1β Expression in In Vitro Models
by: Tri Astiawati, et al.
Published: (2025-03-01) -
Bystander monocytic cells drive infection-independent NLRP3 inflammasome response to SARS-CoV-2
by: Leon L. Hsieh, et al.
Published: (2024-10-01) -
NLRP12-associated periodic syndrome: A description of the authors' own observation and an analysis of literature data
by: M. F. Dubko, et al.
Published: (2017-04-01)